Exploratory Study of Entire-body PET-CT Scans Using Amyvid Radiotracer for Multiple Sclerosis Evaluation and Monitoring

What this Trial Is About

Researchers are exploring the use of the latest entire-body positron emission tomography (PET) scanners to better evaluate and monitor demyelination in both the peripheral and central nervous system of people with multiple sclerosis (MS). This early phase 1 clinical trial aims to identify differences in the uptake of the radiotracer F18-florbetapir in the white matter of MS patients compared to healthy individuals. The study also looks at psychological health changes in participants who choose to learn their imaging results. Participants will undergo entire-body PET-CT scans using advanced scanners from different manufacturers, including Siemens Biograph Vision and United Imaging uEXPLORER. The study evaluates the binding of Amyvid (F18-florbetapir) to myelinated, demyelinated, or remyelinated white matter throughout the nervous system. The imaging scan requires participants to lie still for 10 to 20 minutes during the procedure. During the study, participants will have a single PET-CT scan lasting one day. Psychological health will be monitored with questionnaires over a period of up to 90 days for those who opt to receive their imaging results. Researchers will measure radiotracer activity in nervous system tissues and track mental well-being changes following disclosure of scan results. This pilot study involves a total of 20 participants and includes evaluations to ensure safe and effective data collection.

Entire-body PET Scans for Multiple Sclerosis